Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant. Issue 8 (3rd August 2017)

• Record Type: Journal Article
• Authors: Goldberg, Jenna D.; Zheng, Junting; Ratan, Ravin; Small, Trudy N.; Lai, Kuan-Chi; Boulad, Farid; Castro-Malaspina, Hugo; Giralt, Sergio A.; Jakubowski, Ann A.; Kernan, Nancy A.; O'Reilly, Richard J.; Papadopoulos, Esperanza B.; Young, James W.; van den Brink, Marcel R.M.; Heller, Glenn; Perales, Miguel-Angel
• Is Part Of: Leukemia & lymphoma. Volume 58:Issue 8(2017)
• Page Start: 1859
• Page End: 1871
• Publication Date: 2017-08-03
• Subjects: Immune reconstitution -- allogeneic hematopoietic stem cell transplant -- T-cell depletion; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2016.1265113
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TCD). To characterize the pattern of immune reconstitution in the first year after transplant and its effects on survival and relapse, we performed a retrospective study in 375 recipients of a myeloablative TCD allo-HSCT for hematologic malignancies. We noted that different subsets recover sequentially, CD8 + T cells first, followed by total CD4 + and naïve CD4 + T cells, indicating thymic recovery during the first year after HSCT. In the multivariate model, a fully HLA-matched donor and recovery of T-cell function, assessed by PHA response at 6 months, were the only factors independently associated with OS and EFS. In conclusion, T-cell recovery is an important predictor of outcome after TCD allo-HSCT.